Allosteric Modulator Compositions for Refractory Epilepsy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for epileptic disorders, particularly those involving allosteric modulators and gaboxadol, face challenges in efficacy and safety, especially in cases of status epilepticus and refractory seizures.
Innovation Solution
The use of pharmaceutical compositions containing allosteric modulators, such as neurosteroids, benzodiazepines, and potassium channel openers, either alone or in combination with gaboxadol or its pharmaceutically acceptable salts, to treat a wide range of epileptic disorders, including status epilepticus and Scn1a-related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional anti-epileptic medications are used, then treatment is limited to patients who do not respond to traditional medications, but the patent provides effective treatment for refractory and super refractory status epilepticus
Solution Approach 1:
The patent employs parameter changes by transitioning from traditional GABA_A receptor modulators to a dual-acting compound that simultaneously modulates GABA_A and GABA_B receptors. This fundamental pharmacological parameter change enables the treatment to overcome resistance mechanisms in refractory and super refractory status epilepticus patients, expanding efficacy to previously untreatable populations while maintaining targeted receptor interaction
2Reliability
If gaboxadol is used as a selective GABAA receptor agonist, then it shows efficacy in early studies, but development is terminated due to psychiatric adverse events in patients with drug abuse history
Solution Approach 1:
The patent merges the actions of two previously separate pharmacological targets into a single compound: GABA_A receptor modulation (providing anticonvulsant efficacy) and GABA_B receptor modulation (providing protective effects against adverse events). This combination approach allows the compound to achieve therapeutic benefits while mitigating the psychiatric adverse events that terminated gaboxadol development, as the dual mechanism provides a more favorable safety profile
Solution Approach 2:
The patent converts the potential harm of selective GABA_A agonism (which caused psychiatric adverse events) into a benefit by adding GABA_B modulation. The GABA_B component acts as a protective mechanism that reduces the harmful psychiatric effects while preserving the anticonvulsant benefits, effectively transforming the original harm into a therapeutic advantage through the dual-receptor approach
3Stability of the object's composition
If parenteral formulations include excipients to enhance solubility and stability, then active ingredient solubility and stability are improved, but excipients may produce negative effects such as loss of drug solubility, activity, and stability
Solution Approach 1:
The patent applies parameter changes by utilizing pH adjustment through buffers to optimize the solubility and stability parameters of the active ingredient. By controlling the pH environment, the formulation achieves enhanced drug stability and solubility without relying on excipients that could cause negative effects such as precipitation or degradation, thus resolving the contradiction between stability enhancement and harmful excipient effects
Data Source
AI summary
Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.